

**EFFECTS OF VILDAGLIPTIN ON THE PITUITARY– GONADAL AXIS OF MALE  
WISTAR RATS**

**By**

**AZEEZ Taoreed Adegoke**

**MB.,Ch.B. Ife**

**BMSP12/13/H/0918**

**A Thesis Submitted to the Department of Physiological Sciences, Faculty of Basic Medical  
Sciences, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.**

**In Partial Fulfillment of the Requirement for the Award of Master of Science (M.Sc.)  
Degree in Physiology.**

**2016**

**AUTHORIZATION TO COPY**

OBAFEMI AWOLOWO UNIVERSITY, ILE-IFE, OSUN STATE, NIGERIA

HEZEKIAH OLUWASANMI LIBRARY

POSTGRADUATE THESIS

**AUTHOR:** AZEEZ Taoreed Adegoke

**TITLE:** Effects of Vildagliptin on the pituitary–gonadal axis of male Wistar rats

**DEGREE:** M.Sc. (Physiology)

**YEAR:** 2016

I, AZEEZ Taoreed Adegoke, hereby authorize the Hezekiah Oluwasanmi Library to copy my thesis in part or in response to request from individuals and or organizations for the purpose of private study or research.

.....  
Signature

.....  
Date

### CERTIFICATION

This is to certify that this research work was carried out by AZEEZ Taoreed Adegoke with the registration number BMSP12/13/H/0918, under our close supervision in the Department of Physiological Sciences, Faculty of Basic Medical Sciences, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.

.....  
Dr. O. S. Akinsomisoye  
(Supervisor)

.....  
Dr. A. R. Owolabi  
(Co-supervisor)

.....  
Dr. O. Ogunlade  
(Ag. Head, Department of Physiological Sciences, OAU, Ile-Ife).

## DEDICATION

This work is dedicated to God, the Pedestal of my existence and subsistence. He has created me specially and has enabled me to accomplish this enormous task. He has turned a creature into a creator; creativity without an end. To Him alone be all the glory.

## ACKNOWLEDGEMENTS

I genuinely acknowledge God, the creator of heaven and earth, without whom the work would have been a grandiose effort in robust futility. He has been my irremovable Rock of ages, my fortress and my all-in-all.

My sincere appreciation goes to my indefatigable supervisor, Dr. O. S. Akinsomisoye. He has painstakingly gone through the work and made significant contributions towards its success. His brilliant ideas at different stages of the work were second to none. He is a worthy role model.

I consider myself fortunate to have an erudite Pharmacologist, Dr. A. R. Owolabi as my co-supervisor. He made me see the work from a panoramic perspective. His immense contributions cannot be overemphasized.

I also express my gratitude to the Head of the Department, Dr. O. Ogunlade for his moral support and encouragement. He showed genuine concern, especially when I was literally navigating against the tides of time. I also appreciate the support of other lecturers in the Department namely, Dr. R.O. Akomolafe, Dr. A.O. Ayoka, Mr. Olukiran and Mr. Adu.

I must also acknowledge the impact of Dr. Salami, a Consultant Pathologist, who assisted with the interpretation of the micrographs. Mr. Ibraheem Kareem, Mr. Olaleye and Dr. Oluwasanjo were all supportive in one way or the other. My special thanks go to Chris Imafidon who played a tremendous role towards the accomplishment of this task

I am also grateful to my parents Alhaji and Mrs. M.A. Azeez. They have been the vehicle that conveyed me to a platform of success in succession. I must appreciate my heartthrob, Tolu Morountonu. She has been a lubricant to my engine.

To the aforementioned people and other well-wishers too numerous to mention, I say *merci beaucoup*. May the Lord bless you (Amen).

OBAFEMI AWOLOWO UNIVERSITY



## Table of Contents

Title page	i
Authorization	ii
Certification	iii
Dedication	iv
Acknowledgements	
v	
Table of Contents	vii
List of Tables	xiii
List of Figures	xv
List of Plates	xvii
Abstract	xviii
<b>CHAPTER ONE</b>	<b>1</b>
1.0 Introduction	1
1.1.0 Diabetes mellitus	1
1.2.0 Antidiabetic drugs	2
1.3.0 Vildagliptin	4
1.4.0 Diabetes mellitus and infertility	4
1.5.0 Objectives of the study	5
1.6.0 Statement of research problem	6
1.7.0 Expected contribution to knowledge	6

<b>CHAPTER TWO</b>	<b>7</b>
2.0 Literature Review	7
2.1.0 Epidemiology of diabetes mellitus	7
2.2.0 Management of diabetes mellitus	12
2.3.0 Pharmacologic therapy of diabetes mellitus	14
2.3.1 Biguanides	16
2.3.2 Sulphonylureas	17
2.3.3 Meglitinides	18
2.3.4 Alpha-glucosidase inhibitors	19
2.3.5 Thiazolidinediones	20
2.3.6 Glucagon-like peptide-1 agonists	20
2.3.7 Dipeptidyl peptidase-4 inhibitors	21
2.3.8 Selective sodium-glucose transporter-2 inhibitor	22
2.3.9 Insulin	22
2.3.10 Amylinomimetics	24
2.4.0 Adverse effects of antidiabetic drugs	24
2.5.0 Reproductive system and the antidiabetic agents	25
2.6.0 Pharmacology of Vildagliptin	26
2.6.1 Mechanism of action	27
2.6.2 Pharmacodynamic effects	27
2.6.3 Therapeutic indications	28
2.6.4 Posology of Vildagliptin in adults	28





2.6.5	Pharmacokinetic properties	29
2.6.6	Adverse effects of Vildagliptin	30
2.7.0	Hypothalamic-pituitary-gonadal axis	31
2.7.1	Hypothalamic-pituitary-testicular system	31
2.8.0	Gonadotropin-releasing hormone	34
2.9.0	The pituitary gland	35
2.9.1	Follicle-stimulating hormone	37
2.9.2	Luteinizing hormone	38
2.10.0	Gonads	39
2.11.0	Male reproductive system	40
2.11.1	Testes	40
2.11.1.1	Testicular hormones	42
2.11.1.2	Testosterone	43
2.11.1.3	Inhibin	44
2.11.1.4	Oestradiol	45
2.11.2	Epididymis	46
2.11.3	Vas deferens	47
2.11.4	Penis	47

2.11.5 Male accessory organs	48
2.12.0 Spermatogenesis	48
2.12.1 Stages of spermatogenesis	50
2.13.0 Semen analysis	53
2.13.1 Sperm count	55
2.13.2 Sperm morphology	55
2.13.3 Sperm motility	58
2.13.4 Sperm viability	58
2.14.0 Infertility in rats	59
2.14.1 Male infertility	60
2.14.2 Male infertility and diabetes	60
2.14.3 Male infertility and drugs	61
2.14.4 Female infertility	62
2.15.0 Mating	62
2.16.0 Gestation and delivery	64
2.17.0 Litter size	65



<b>CHAPTER THREE</b>	<b>67</b>
3.0 Materials and methods	67
3.1.0 Animal care and management	67
3.2.0 Drug preparation	67
3.3.0 Experimental design	68
3.4.0 Animal sacrifice	69
3.5.0 Organ weighing	70
3.6.0 Epididymal sperm characteristics – motility, count, morphology and viability	70
3.7.0 Testosterone assay	71
3.8.0 Follicle-stimulating hormone assay	72
3.9.0 Luteinizing hormone assay	73
3.10.0 Histological studies	74
3.11.0 Determination of litter size	74
3.12.0 Statistical analysis	75
<b>CHAPTER FOUR</b>	<b>76</b>
4.0 Results	76
4.1.1 Effect of Vildagliptin on the absolute mean body weight of male	



Wistar rats	76
4.1.2 Effects of Vildagliptin on percentage weight gain of the rats	77
4.1.3 Effect of Vildagliptin on relative testicular weights	78
4.1.4 Effect of Vildagliptin on relative left epididymal weights	78
4.2.1 Effects of Vildagliptin on epididymal sperm count	79
4.2.2 Effects of Vildagliptin on sperm motility	80
4.2.3 Effects of Vildagliptin on sperm viability of Wistar rats	81
4.2.4 Effects of Vildagliptin on sperm morphology of Wistar rats	82
4.3.1 Effects of Vildagliptin on testosterone concentration	83
4.3.2 Effects of Vildagliptin on follicle stimulating hormone concentration	84
4.3.3 Effects of Vildagliptin on luteinizing hormone concentration	85
4.4.0 Effects of Vildagliptin on litter size	86
4.5.0 Effects of Vildagliptin on the histology of the testis of Wistar rats	88
4.6.0 Effects of Vildagliptin on the histology of the epididymis of Wistar rats	92
<b>CHAPTER FIVE</b>	<b>96</b>
5.1.0 Discussion	96
5.2.0 Conclusion	105

5.3.0 Recommendation

106

**REFERENCES****10****APPENDIX****143**

OBAFEMI AWOLOWO UNIVERSITY



<b>List of tables</b>	<b>Page</b>
Table 1: Classes of antidiabetic drugs and their mechanisms of action	15
Table 2: Various preparations of insulin	23
Table 3: Table showing the effects of Vildagliptin on the absolute body weights of male Wistar rats	144
Table 4: Table showing the effects of Vildagliptin on the percentage weight gain of male Wistar rats	144
Table 5: Table showing the effects of Vildagliptin on the relative testicular weight of male Wistar rats.	145
Table 6: Table showing the effects of Vildagliptin on the relative epididymal weight of male Wistar rats.	145
Table 7: Table showing the effects of Vildagliptin on the sperm counts of male Wistar rats	146
Table 8: Table showing the effects of Vildagliptin on the sperm motility of male Wistar rats	146
Table 9: Table showing the effects of Vildagliptin on the sperm viability of male Wistar rats	147
Table 10: Table showing the effects of Vildagliptin on the sperm morphology	

of male Wistar rats.	147
Table 11: Table showing the effects of Vildagliptin on the testosterone concentration	
of male Wistar rats	148
Table 12: Table showing the effects of Vildagliptin on the FSH concentration	
of male Wistar rats.	148
Table 13: Table showing the effects of Vildagliptin on the LH concentration of	
male Wistar rats	149
Table 14: Table showing effectsof Vildagliptin on the average litter size of Wistar	
rats	149

<b>List of figures</b>	<b>Pages</b>
Figure 1: Global trends in the epidemiology of diabetes mellitus	11
Figure 2: The global prevalence of diabetes mellitus	11
Figure 3: Multidisciplinary management of diabetes mellitus	13
Figure 4: Mechanisms of action of antidiabetic drugs	16
Figure 5: Chemical structure of metformin	17
Figure 6: Mechanism of action of the sulphonylureas	18
Figure 7: Examples of meglitinides	19
Figure 8: Alpha-glucosidase inhibitors; structures and doses	19
Figure 9: Thiazolidinediones; structures and doses	20
Figure 10: Chemical structure of Vildagliptin	26
Figure 11: Hypothalamic-pituitary-testicular axis	33
Figure 12: The chemical structure of GnRH	35
Figure 13: The pituitary gland	37
Figure 14: Testis	43
Figure 15: Testosterone and dihydrotestosterone	44
Figure 16: Inhibin	45



Figure 17: Parts of the epididymis and testis	47
Figure 18: Cross section of the seminiferous tubule	49
Figure 19: Stages of spermatogenesis	52
Figure 20: The structure of a spermatozoon	54
Figure 21: Light microscopy of normal spermatozoa	54
Figure 22: Relationship between sperm count and pregnancy rate	55
Figure 23: Examples of abnormal sperm morphology	57
Figure 24: Effects of Vildagliptin (VDG) on absolute body weights of male Wistar rats	76
Figure 25: Effects of Vildagliptin (VDG) on percentage weight gain of male Wistar rats	77
Figure 26: Effects of Vildagliptin (VDG) on the relative testicular weights of male Wistar rats	78
Figure 27: Effects of Vildagliptin (VDG) on the relative epididymal weights of male Wistar rats	79
Figure 28: Effects of Vildagliptin (VDG) on the sperm counts of male Wistar rats	80
Figure 29: Effects of Vildagliptin (VDG) on the sperm motility of male Wistar rats	81
Figure 30: Effects of Vildagliptin (VDG) on the sperm viability of male Wistar rats	82
Figure 31: Effects of Vildagliptin (VDG) on the sperm morphology of male Wistar rats	83
Figure 32: Effects of Vildagliptin (VDG) on the testosterone concentration of male Wistar rats.	84
Figure 33: Effects of Vildagliptin (VDG) on the FSH concentration of male Wistar rats	85
Figure 34: Effects of Vildagliptin (VDG) on the LH concentration of male Wistar rats	86
Figure 35: Effects of Vildagliptin on average litter size	87

<b>List of plates</b>	<b>Pages</b>
Plate 1: Photomicrographs of the testes of control group and treated groups after 8 weeks of treatment. X 100 magnification	88
Plate 2: Photomicrographs of the testes of control group and treated groups after 8 weeks of treatment. X 400 magnification	89
Plate 3: Photomicrographs of the testes of control group and treated groups after 8 weeks of treatment and another 8 weeks of drug-free recovery period. X 100 magnification	90
Plate 4: Photomicrographs of the testes of control group and treated groups after 8 weeks of treatment and another 8 weeks of drug-free recovery period. X 400 magnification	91
Plate 5: Photomicrographs of the epididymis of control group and treated groups after 8 weeks of treatment. X 100 magnification	92
Plate 6: Photomicrographs of the epididymis of control group and treated groups after 8 weeks of treatment. X 400 magnification	93
Plate 7: Photomicrographs of the epididymis of control group and treated groups after 8 weeks of treatment and another 8 weeks of drug-free recovery period. X 100 magnification	94
Plate 8: Photomicrographs of the epididymis of control group and treated groups after 8 weeks of treatment and another 8 weeks of drug-free recovery period. X 400 magnification	95

### Abstract

This study investigated the effects of daily administration of Vildagliptin (an oral anti-diabetic drug) for eight weeks on some sperm parameters, pituitary as well as gonadal hormones, litter size and testicular with epididymal histology of male Wistar rats.

A total of 60 male and 40 female Wistar rats weighing 120 - 150 g were used for the study. The 60 male rats were divided into 3 equal categories (A, B and C). Each category was further divided into 4 groups (making a total of 12 groups), with each group containing 5 rats. In category A, Group 1, the control group, received 1.4 ml/kg of distilled water daily for 8 weeks; while Groups 2, 3, and 4 received 0.35 mg/kg, 0.70 mg/kg and 1.4 mg/kg of Vildagliptin (orally) daily for 8 weeks respectively. Thereafter, the rats were sacrificed to determine the following parameters: sperm characteristics (count, motility, viability and morphology), serum testosterone, follicle-stimulating hormone and luteinizing hormone concentrations. Histology of the testis and epididymis was done. In category B, Group 5, the control group, received 1.4 ml/kg of distilled water daily for 8 weeks via oral route; while Groups 6, 7, and 8 received 0.35 mg/kg, 0.70 mg/kg and 1.4 mg/kg of Vildagliptin (orally) daily for 8 weeks respectively. Thereafter, each male rat was allowed to cohabit (so as to mate) with 2 apparently healthy non-pregnant female rats in separate cages. The litter sizes were determined and summed up for each group. In category C, Group 9, the control group, received 1.4 ml/kg of distilled water daily for 8 weeks; while Groups 10, 11, and 12 received 0.35mg/kg, 0.70 mg/kg and 1.4 mg/kg of Vildagliptin (orally) daily for 8 weeks respectively. All the rats were allowed another 8 weeks of drug-free recovery period. Subsequently, they were sacrificed and the same parameters (as listed for category A) were determined.

The results of the study showed a dose-independent but partly reversible significant decrease in the sperm counts ( $\times 10^6$  /ml) of all the Vildagliptin-treated groups when compared with the control ( $F=3.89$ ,  $p=0.045$ ). There was a dose-independent but reversible significant reduction in the sperm motility (%) of the treated groups when compared with the control ( $F=9.84$ ,  $p=0.0015$ ). There was a dose-independent but reversible significant increase in the percentage of sperms with abnormal morphology in the treated groups when compared with the control ( $F=4.39$ ,  $p=0.026$ ). However, there was no significant change in sperm viability ( $F=1.00$ ,  $p=0.43$ ). There was a dose-independent significant decrease in serum testosterone ( $F=4.51$ ,  $p=0.040$ ) and significant increase in serum FSH ( $F=4.39$ ,  $p=0.037$ ) as well as delayed significant increase in LH ( $F=4.39$ ,  $p=0.037$ ) of the treated rats when compared with the control. There was a highly significant dose-dependent decrease in the litter size of treated rats when compared with the control ( $F=18.66$ ,  $p<0.0001$ ). There was no visible deleterious effect on the histoarchitecture of the testes of the treated rats, however there was a dose-dependent distortion in the histoarchitecture of the epididymis of the rats in the treated groups when compared with the control and these were largely reversible after 8 weeks of recovery.

In conclusion, Vildagliptin adversely affected the reproductive structure and function of male Wistar rats. It caused significant deleterious effects on the sperm counts, motility, morphology, epididymal histology as well as the serum testosterone, FSH and LH with resultant decrease in litter size. Further studies will be required to characterize these effects at the molecular level and to devise the means of mitigating the effects.

## CHAPTER ONE

### 1.0 INTRODUCTION

#### 1.1.0 Diabetes mellitus

Diabetes mellitus is a group of metabolic diseases in which there are high blood glucose levels over a prolonged period of time due to deficiency in insulin secretion and/or action (WHO, 2014). Diabetes mellitus is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces (Alberti and Zimmet, 1998). If left untreated, diabetes mellitus can cause many complications. Acute complications include diabetic ketoacidosis and hyperglycaemic hyperosmolal state (Kitabchi *et al.*, 2009). Serious long term complications include cardiovascular diseases, chronic kidney disease, foot ulcers and damage to the eyes.

There are 4 types of diabetes mellitus: type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes mellitus and other specific types (ADA, 1979). Adopting a healthy lifestyle is a critical part of delaying or preventing the onset of diabetes. However, for those already diagnosed with the disease, keeping it under control is very important. In many cases, medications are integral parts of the management.

In 2014, the global prevalence of diabetes was estimated to be 9% among adults aged 18 and above (WHO, 2014). In 2012, an estimated 1.5 million deaths were directly caused by diabetes (WHO, 2012). More than 80% of diabetes incidence occur in low-income and medium-income countries (WHO, 2012). The World Health Organization projects that diabetes mellitus

will be the 7<sup>th</sup> leading cause of death in 2030 (Mathers and Loncars, 2006). 50% of people with diabetes mellitus die of cardiovascular diseases (Morrish *et al.*, 2001).

Insulin is a hormone that regulates blood glucose, among other things. Hyperglycaemia is a common effect of uncontrolled diabetes and over time, it leads to serious damage to many of the body systems, especially the nerves and blood vessels. Impaired glucose tolerance and impaired fasting glucose are intermediate conditions in the transition between normality and diabetes mellitus (NICE, 2012). People with these conditions are at high risk of progressing to type 2 diabetes although this is not inevitable. Early diagnosis can be achieved through relatively inexpensive blood testing. Treatment of diabetes involves lowering blood glucose and the level of other known risk factors that damage blood vessels and nerves.

### **1.2.0 Antidiabetic drugs**

Antidiabetic agents consist of any of the several drugs that are used to control the level of glucose in the blood. They are developed to stabilize blood glucose levels in people with diabetes mellitus. Except few ones like insulin, exenatide and liraglutide, they are mostly administered orally hence, the term 'oral antihyperglycaemic agents' (Koski, 2006).

There are different classes of antidiabetic drugs and determining which one to use depends on the nature of the diabetes, age, severity of the illness, as well as other factors (Harrigan *et al.*, 2001). The main classes are heterogeneous in their modes of action, safety profiles and tolerability (Krentz and Bailey, 2005). When choosing an agent, it is prudent to consider both patient-specific and drug-specific characteristics (Luna and Feinglos, 2001). The various classes of antidiabetic drugs include insulin, biguanides, thiazolidinediones, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, glucagon-like peptide agonists,

dipeptidyl peptidase-4 inhibitors, amylin analogues and sodium-dependent glucose co-transporter-2 (SGLT-2) inhibitors (Moses *et al.*, 2014).

Each class has its own mechanism of action, although some mechanisms of actions are interrelated. If adequate glucose control is not attained using a single oral agent, a combination of agents with different mechanisms of action may have additive therapeutic effects and result in better glycaemic control (Luna and Feingos, 2001).

Insulin injection serves as a replica of endogenously-produced insulin. So, they have the same mechanism of action which involves uptake of glucose by the insulin-sensitive cells (Alegbejo *et al.*, 2014). Biguanides reduce hepatic glucose output and increase uptake of glucose by the periphery including the skeletal muscle. Thiazolidinediones bind to peroxisome proliferator-activated receptor gamma (PPAR- $\gamma$ ), a type of nuclear regulatory protein involved in transcription of genes regulating glucose and fat metabolism (Bermudez *et al.*, 2010).

Sulphonylureas trigger insulin release by inhibiting a specific type of potassium channel on the pancreatic beta cells. Meglitinides act on the same potassium channel as sulfonylureas, but at a different binding site. Alpha-glucosidase inhibitors slow the digestion of carbohydrate in the small intestine thereby allowing glucose to enter into the blood stream more slowly (Osadebe *et al.*, 2014). Glucagon-like peptide-1 agonists bind to a membrane glucagon-like peptide-1 receptor thereby increasing the release of insulin from beta cells. Amylin analogues slow gastric emptying and suppress glucagon secretion. Sodium-dependent glucose co-transporter-2 (SGLT-2) inhibitors block the re-uptake of

For more information, please contact **[ir-help@oauife.edu.ng](mailto:ir-help@oauife.edu.ng)**